Telephone
61.3.9545.5940
Address
700 Swanston Street Level 7 Carlton, Victoria (VIC) 3053
Description
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. It develops pipeline products that may assist physicians to more effectively diagnose and manage patients with lung disease, which includes XV ventilation analysis, ventilation perfusion, contrast free pulmonary angiography, small animal ventilator, and preclinical scanner. The company was founded by Andreas Fouras in December 2012 and is headquartered in Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.22 - 0.71
Trade Value (12mth)
AU$93,393.00
1 week
9.8%
1 month
-24.32%
YTD
-41.67%
1 year
-53.33%
All time high
2.98
EPS 3 yr Growth
18.60%
EBITDA Margin
%
Operating Cashflow
-$31m
Free Cash Flow Return
-40.90%
ROIC
-47.70%
Interest Coverage
-167.30
Quick Ratio
1.70
Shares on Issue (Fully Dilluted)
413m
HALO Sector
Technology
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.04
Date | Announcements |
---|---|
16 April 25 |
Supplementary Prospectus
×
Supplementary Prospectus |
16 April 25 |
Revised Target Market Determination
×
Revised Target Market Determination |
15 April 25 |
4DMedical converts Integral Diagnostics pilot into contract
×
4DMedical converts Integral Diagnostics pilot into contract |
15 April 25 |
Change of registry address
×
Change of registry address |
11 April 25 |
Notification of cessation of securities - 4DX
×
Notification of cessation of securities - 4DX |
10 April 25 |
4DMedical wins industry partners and discussed in Congress
×
4DMedical wins industry partners and discussed in Congress |
01 April 25 |
Letter to Shareholders, Notice of EGM & Proxy Form
×
Letter to Shareholders, Notice of EGM & Proxy Form |
26 March 25 |
Cost reduction program delivers $6.5m in annualised savings
×
Cost reduction program delivers $6.5m in annualised savings |
25 March 25 |
4DMedical completes oversubscribed $8.4m SPP
×
4DMedical completes oversubscribed $8.4m SPP |
25 March 25 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
25 March 25 |
Prospectus
×
Prospectus |
25 March 25 |
Target Market Determination
×
Target Market Determination |
11 March 25 |
3-year contract extension secured with the Cleveland Clinic
×
3-year contract extension secured with the Cleveland Clinic |
03 March 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
03 March 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
03 March 25 |
Notification of cessation of securities - 4DX
×
Notification of cessation of securities - 4DX |
28 February 25 |
Appendix 4D and Half-Year Report
×
Appendix 4D and Half-Year Report |
28 February 25 |
1H FY2025 Half-year results
×
1H FY2025 Half-year results |
28 February 25 |
1H FY2025 Investor Presentation
×
1H FY2025 Investor Presentation |
28 February 25 |
Cleansing Notice - Placement
×
Cleansing Notice - Placement |
28 February 25 |
Change in substantial holding
×
Change in substantial holding |
28 February 25 |
Change in substantial holding
×
Change in substantial holding |
28 February 25 |
Change in substantial holding
×
Change in substantial holding |
27 February 25 |
Webinar details - 1H FY2025 Half Year Results
×
Webinar details - 1H FY2025 Half Year Results |
27 February 25 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.